Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An inactivated Zika virus vaccine

A Zika virus and vaccine technology, applied in the field of biopharmaceuticals, can solve the problems of blank culture process, purification process and preparation process, vaccine immunogenicity and stability need to be studied, etc., to avoid Brazilian microcephaly, reduce Operation steps, cost reduction effect

Active Publication Date: 2020-09-11
SINOVAC RES & DEV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no Zika vaccine available so far, and the immunogenicity and stability of the vaccine need to be studied
[0008] Due to the sudden outbreak of Zika virus in this epidemic, although Zika virus has been isolated since the 1950s, there are few literatures describing Zika virus, and its cultivation process, purification process and preparation process are still blank

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An inactivated Zika virus vaccine
  • An inactivated Zika virus vaccine
  • An inactivated Zika virus vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1 Preparation of Cell Working Seed and Preparation of Virus Liquid

[0044] 1. Preparation of high-density cell working seeds

[0045] Use 199 culture medium to dilute Vero main cell seed dilution ratio to 60:1, inoculate to 175cm 2 Cells were cultured in square flasks at a temperature of 36.0°C±1°C. After the cells are fully covered with the cell bottle, continue passage for 4 generations according to the ratio of 1:4 to 1:6. The last generation was transferred to five 40-layer cell factories, trypsinized, and centrifuged to remove the supernatant. Use freezing solution containing 10% DMSO to resuspend, and the cell concentration after mixing is 2.5×10 7 pieces / ml. The cell seeds were subjected to gradient cooling in a temperature program cooling device, keeping the temperature down by 1°C per minute. After the temperature drops to -196°C, it is stored in liquid nitrogen, and the working cell seeds are valid for 10 years.

[0046] 2. Vero cell culture

...

Embodiment 2

[0051] Example 2 Screening of Medium

[0052] Select commercially available MEM, M199, DMEM, DMEM / F12 medium, use the DOE software of Minitab17 for experimental design, carry out virus culture according to the designed medium formula, compare the results of virus titer and virus immunogenicity, and choose the best Medium. The medium formula of the experimental design is shown in Table 1, wherein "1" represents adding the medium, and "-1" represents not adding the medium. If there are several "1" in the recipe, make several equal parts, and each medium is divided into one equal part. The results of virus titer and immunogenicity are shown in Table 2 and Table 3, wherein the medium in which M199 and DMEM / F12 are mixed in equal volume at 1:1 produces significantly higher virus immunogenicity and titer than other mediums.

[0053] Table 1 DOE test medium formula

[0054]

[0055]

[0056] Table 2 Virus titer results

[0057] formula Titer results (CCID 50 / m...

Embodiment 3

[0061] Example 3 Zika virus inactivation and purification

[0062] 1. Inactivation of Zika virus Add formaldehyde at a final concentration of 200 μg / ml to the Zika virus harvest solution, and inactivate it at 37°C for 7 days. That is, the inactivation of Zika virus is completed.

[0063] 2. Purification of Zika virus

[0064] (1) Clarification Filter the virus liquid through filter elements with continuous three-stage pore diameters of 3-0.8 μm, 0.8-0.65 μm, and 0.65-0.22 μm or centrifuge (including continuous flow centrifugation) with a speed of 2000-5000 rpm and a centrifugation time of 0.5-4 hours, to obtain virus clarification;

[0065] (2) Concentration The virus clarified liquid was concentrated by a Pall tangential flow membrane filtration system with a molecular weight cut-off of 300KD, and the concentration factor was 100 times.

[0066] (3) Density gradient centrifugation The low and high concentrations of the sucrose solution are 25% and 55% respectively. The de...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides an inactivated Zika virus vaccine. The inactivated Zika virus vaccine is obtained by: performing ultrafiltration and concentration on Zika virus liquid after inactivation, centrifuging the concentrated virus liquid by adopting a sucrose density zone, performing ion exchange and concentration sterilization on a centrifugal product to obtain a Zika virus vaccine stock solution, diluting the vaccine stock solution until the total protein content is not more than 20mu g / ml, and adding an adjuvant to obtain a vaccine semi-finished product. The method for preparing the vaccine provided by the invention is simple, convenient and easy to operate, the cost is saved, the produced vaccine is suitable for Asian people, a unit dose of the Zika virus liquid is high in immunogenicity, the content of hybrid protein is low, the side effect after injection is small, and the safety is high, so that the vaccine is suitable for vaccination of fertile women before pregnancy, can avoid newborn Brazil microcephaly caused by infection of Zika virus, and is significant in social value and market efficiency.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals, in particular to an inactivated Zika virus vaccine. Background technique [0002] Zika virus disease is a self-limiting acute infectious disease caused by Zika virus and transmitted by mosquitoes. Zika virus was first identified in rhesus monkeys in Uganda in 1947, and was isolated in humans in Uganda and Tanzania in 1952. Before 2007, only 14 sporadic cases of Zika virus disease were reported in the world. In 2007, Zika virus outbreak was first discovered in Yap Island, Micronesia, a Pacific island country. There is an increasing trend in countries and regions. In May 2015, Brazil reported its first case of Zika virus disease. As of the end of January 2016, local infection cases had been found in 24 American countries and regions including Brazil. At the same time, imported cases were found in many countries in Europe, North America and other places, and Taiwan also reported an imported case...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/12A61P31/12
CPCA61K39/12C12N2770/24034Y02A50/30
Inventor 王琳吕哲惠增弟高强
Owner SINOVAC RES & DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com